投资要点:近期观点1、医药指数本周关注的6 个子行业中5 个录得正收益,表现良好。2、厦门大学与神威药业联合研发的中药新药“枇杷清肺饮颗粒”近日获批上市,该药品源于清代《医宗金鉴》所载古方,是中药经典名方“免临床”审批政策落地的标志性成果。团队通过构建“药材-饮片-中间体-制剂”全过程质量控制体系,实现传统智慧的现代转化,为行业提供了可复制的研发范式。这一进展凸显中药行业在政策支持与技术创新的双轮...
Source Link投资要点:近期观点1、医药指数本周关注的6 个子行业中5 个录得正收益,表现良好。2、厦门大学与神威药业联合研发的中药新药“枇杷清肺饮颗粒”近日获批上市,该药品源于清代《医宗金鉴》所载古方,是中药经典名方“免临床”审批政策落地的标志性成果。团队通过构建“药材-饮片-中间体-制剂”全过程质量控制体系,实现传统智慧的现代转化,为行业提供了可复制的研发范式。这一进展凸显中药行业在政策支持与技术创新的双轮...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.